Indeed, pilot data from a phase I clinical trial has shown that small-molecule inhibitors of EP4 are well tolerated and slowed disease progression in a proportion of patients with advanced cancers [147], while pre-clinical studies have demonstrated that COX-2 inhibition synergises with ICB to improve tumour eradication, highlighting its potential as a therapeutic adjuvant [148]. This evidence concerns the gene PTGER4 and cancer.